REPL

Conviction 86HealthcareScan · Mon, Aug 10, 2026

REPL$13.67+13.35%

ResistanceSupportVol 14Insider sell

Vol MA14 10.13M

May 11May 28Jun 16Jul 6Jul 23Aug 10

WSB mentions · 24h changelatest +50.00%· 3 mentions

May 11May 28Jun 16Jul 6Jul 23Aug 10

Replimune Group, Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.replimune.com ↗

Price13.67

Change+13.35%

Gap+4.73%

Rel volume1.94×

Avg volume8.12M

Avg $ vol80.06M

SMA 209.83

SMA 5010.05

SMA 2007.99

Price vs 50+36.05%

Price vs 200+71.02%

MA stackbullish

50/200 cross—

Supertrendup · 6.14

RSI (14)60

MACD hist0.56

MACD crossbull · 4d

Stoch %K / %D97 / 92

ADX (14)28

+DI / −DI41 / 23

RSI divergence—

MACD divergence—

ATR %+15.46%

ADR %13.13%

52w high13.67

52w low0.0000

From 52w high+0.00%

Above 52w low—

New 52w highYes

SqueezeOff

Bollinger width123.62%

%B0.82

Donchian pos96.92%

Donchian high14.11

Donchian low0.0000

AVWAP (52w high)13.36

vs AVWAP high+2.31%

AVWAP (52w low)11.74

vs AVWAP low+16.41%

OBV trendUp

Chaikin MF (20)0.05

Today vs 20d1.94×

Avg vol (14d)10.13M

Avg vol (20d)8.12M

Avg $ vol (20d)80.06M

Market cap1.15B

RS 3m (vs SPY)+255.38%

RS 6m (vs SPY)+59.91%

RS line new highNo

Trend template5/8

Technical rank94.5

1 week+14.78%

1 month+24.39%

3 months+235.87%

6 months+76.39%

1 year+149.45%

YTD+53.60%

P/E-3.66

P/B6.91

P/S—

P/FCF-4.06

EPS-3.38

Div yield—

ROE-188.94%

ROA-94.45%

Debt/Eq0.50

Current4.79

EV/EBITDA-3.23

Gross margin—

Net margin—

Rev growth—

EPS growth-26.95%

Price target17.40

Target upside27.29%

Analyst ratingBuy

Institutional104.85%

Ent. value1.02B

Revenue0

Net income-70.93M

Gross profit—

Free cash flow-282.61M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out82.57M

Employees479

ListedFri, Jul 20, 2018

Free float62.65M

Float %75.9%

Short interest23.65M

Days to cover9.4d

Short volume43.8%

Squeeze score82 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.76 vs −$0.73

Last surprise-4.1% miss

Setup gradeA+

Conviction86 / 100

Pattern quality—

Tech rank94.5 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance12.37

Support4.46

Days since event—

Candle confirm—

News sentiment—

Financials as of Wed, Dec 31, 2025 · quarterly.

Signal lifecycle

How this symbol has moved through the lanes across 47 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.

Setting up
Jun 18
1 scan
→
Breaking out now
Jun 22
1 scan

Congress activity

Disclosed STOCK Act trades in REPL

All disclosures →

No recent disclosed trades by Congress in REPL. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in REPL · 7 sells

Insider	Side	Shares	Value	Traded	Filed
Sarchi Christopher Chief Commercial Officer · Common Stock · 2026-06-01	Sell	12K	$111K	2026-06-01	2026-06-03
Xynos Konstantinos Chief Medical Officer · Common Stock · 2026-05-18	Sell	14.02K	$71K	2026-05-18	2026-05-20
Sarchi Christopher Chief Commercial Officer · Common Stock · 2026-05-18	Sell	8.63K	$44K	2026-05-18	2026-05-20
Patel Sushil Chief Executive Officer · Common Stock · 2026-05-18	Sell	37.32K	$190K	2026-05-18	2026-05-20
Schwendenman Andrew Chief Accounting Officer · Common Stock · 2026-05-18	Sell	7.89K	$40K	2026-05-18	2026-05-20
Hill Emily Luisa Chief Financial Officer · Common Stock · 2026-05-18	Sell	7.81K	$40K	2026-05-18	2026-05-20
Astley-Sparke Philip Director · Common Stock · 2026-05-18	Sell	17.66K	$90K	2026-05-18	2026-05-20

SEC filings

EDGAR filings in REPL · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.